Rad23B: Potential Drug Target Or Biomarker for Neurological Disorders and Cancer

Target Name: RAD23B

NCBI ID: G5887

RAD23B

Rad23B: Potential Drug Target Or Biomarker for Neurological Disorders and Cancer

Rad23B (Protamine 23B) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein has been shown to interact with several other proteins, including tau, a protein that is associated with the development of Alzheimer's disease.

One of the key functions of Rad23B is its role in the formation of neurotransmitter systems, which are the chemical messengers that transmit signals between the brain and other parts of the body. Specifically, Rad23B is involved in the production and degradation of dopamine, a neurotransmitter that is involved in mood, motivation, and other cognitive functions.

In addition to its role in neurotransmitter systems, Rad23B has also been shown to play a key role in the regulation of the immune system. Specifically, the protein has been shown to interact with the immune system protein PDGF-BB, which is involved in the development and progression of various diseases, including cancer.

The potential implications of Rad23B as a drug target or biomarker are significant. If Rad23B is found to be involved in the development and progression of Alzheimer's disease, it could potentially be used as a treatment for this debilitating disease. Additionally, the protein's role in the regulation of the immune system could make it a potential target for cancer treatment.

Research into Rad23B has been ongoing for several years, and while more research is needed, the potential implications of this protein are significant. As such, it is important to continue researching the role of Rad23B in the development and progression of neurological disorders, as well as its potential as a drug target or biomarker.

Protein Name: RAD23 Homolog B, Nucleotide Excision Repair Protein

Functions: Multiubiquitin chain receptor involved in modulation of proteasomal degradation. Binds to polyubiquitin chains. Proposed to be capable to bind simultaneously to the 26S proteasome and to polyubiquitinated substrates and to deliver ubiquitinated proteins to the proteasome. May play a role in endoplasmic reticulum-associated degradation (ERAD) of misfolded glycoproteins by association with PNGase and delivering deglycosylated proteins to the proteasome

The "RAD23B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD23B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets